Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring? (Q36718451)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253884%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

review article

1 reference

title

Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253884%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1 reference

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253884%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

author name string

Karen Dahri

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253884%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253884%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacokinetics

24 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253884%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

volume

46

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253884%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253884%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

page(s)

109-132

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253884%20AND%20SRC:MED&resulttype=core&format=json

Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis

24 December 2019

cites work

1 reference

12 December 2020

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study

1 reference

12 December 2020

Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry

1 reference

12 December 2020

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

1 reference

12 December 2020

No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors

1 reference

12 December 2020

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

1 reference

12 December 2020

Development of an assay method for the detection and quantification of protease and non-nucleoside reverse transcriptase inhibitors in plasma and in peripherical blood mononuclear cells by liquid chromatography coupled with ultraviolet or tandem mas

1 reference

12 December 2020

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring

1 reference

12 December 2020

High-performance liquid chromatographic method for the determination of HIV-1 non-nucleoside reverse transcriptase inhibitor efavirenz in plasma of patients during highly active antiretroviral therapy

1 reference

12 December 2020

High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease

1 reference

12 December 2020

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection

1 reference

12 December 2020

Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.

1 reference

12 December 2020

Simultaneous determination of six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir), the active metabolite of nelfinavir (M8) and non-nucleoside reverse transcriptase inhibitor (efavirenz) in human plas

1 reference

12 December 2020

Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals

1 reference

12 December 2020

Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients

1 reference

12 December 2020

High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma

1 reference

12 December 2020

Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting

1 reference

12 December 2020

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

12 December 2020

Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence

1 reference

12 December 2020

Elevated plasma concentrations of protease inhibitors and nonnucleoside reverse transcriptase inhibitors in patients coinfected with human immunodeficiency virus and hepatitis B or C: case series and literature review.

1 reference

12 December 2020

Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration

1 reference

12 December 2020

Conventional HPLC method used for simultaneous determination of the seven HIV protease inhibitors and nonnucleoside reverse transcription inhibitor efavirenz in human plasma

1 reference

12 December 2020

Drug Transporter and Metabolizing Enzyme Gene Variants and Nonnucleoside Reverse-Transcriptase Inhibitor Hepatotoxicity

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

Are adverse events of nevirapine and efavirenz related to plasma concentrations?

1 reference

12 December 2020

The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers

1 reference

12 December 2020

Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals

1 reference

12 December 2020

Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography

1 reference

12 December 2020

Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz an

1 reference

12 December 2020

Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz

1 reference

12 December 2020

Determination of nevirapine and efavirenz in plasma using GC/MS in selected ion monitoring mode

1 reference

12 December 2020

Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection

1 reference

12 December 2020

Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations

1 reference

12 December 2020

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

1 reference

12 December 2020

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

1 reference

12 December 2020

Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy

1 reference

12 December 2020

Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations

1 reference

12 December 2020

Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry

1 reference

12 December 2020

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

1 reference

12 December 2020

Sensitive enzyme immunoassay for measuring plasma and intracellular nevirapine levels in human immunodeficiency virus-infected patients

1 reference

12 December 2020

Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients.

1 reference

12 December 2020

A potentially significant interaction between efavirenz and phenytoin: a case report and review of the literature

1 reference

12 December 2020

Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz

1 reference

12 December 2020

High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals

1 reference

12 December 2020

Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects

1 reference

12 December 2020

Liver toxicity caused by nevirapine

1 reference

12 December 2020

Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors

1 reference

12 December 2020

Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extractio

1 reference

12 December 2020

Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection

1 reference

12 December 2020

HPLC-UV method for the quantitation of nevirapine in biological matrices following solid phase extraction

1 reference

12 December 2020

Clinical benefit of interventions driven by therapeutic drug monitoring

1 reference

12 December 2020

Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

Determination of twelve antiretroviral agents in human plasma sample using reversed-phase high-performance liquid chromatography.

1 reference

12 December 2020

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

1 reference

12 December 2020

Pharmacogenetics: the therapeutic drug monitoring of the future?

1 reference

12 December 2020

Will pharmacogenomic discoveries improve HIV therapeutics?

1 reference

12 December 2020

Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population

1 reference

12 December 2020

HIV drug interactions: the good, the bad, and the other.

1 reference

12 December 2020

Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all.

1 reference

12 December 2020

High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-li

1 reference

12 December 2020

Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes?

1 reference

12 December 2020